Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study

PURPOSE: To assess the feasibility of adding dose-intensive topotecan and cyclophosphamide to induction therapy for newly diagnosed high-risk neuroblastoma (HRNB). PATIENTS AND METHODS: Enrolled patients received two cycles of topotecan (approximately 1.2 mg/m(2)/d) and cyclophosphamide (400 mg/m(2)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Park, Julie R., Scott, Jeffrey R., Stewart, Clinton F., London, Wendy B., Naranjo, Arlene, Santana, Victor M., Shaw, Peter J., Cohn, Susan L., Matthay, Katherine K.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2011
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3221519/
https://ncbi.nlm.nih.gov/pubmed/22010014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.3293
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares